Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Company Stock

Posted by Geri Gentry on Oct 17th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director James Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $114.81, for a total transaction of $1,148,100.00. Following the transaction, the director owned 1,054,543 shares of the company’s stock, valued at $121,072,081.83. This represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corcept Therapeutics Stock Performance

CORT traded down $3.21 during midday trading on Friday, reaching $110.16. The company had a trading volume of 849,667 shares, compared to its average volume of 1,640,998. The business has a 50-day moving average price of $115.66 and a two-hundred day moving average price of $86.69. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $126.38. The stock has a market cap of $11.91 billion, a PE ratio of 262.29 and a beta of 0.40.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%. The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same quarter last year, the company posted $0.29 EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. On average, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Zacks Research raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research note on Monday, July 27th. Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. HC Wainwright reissued a “buy” rating and issued a $165.00 price objective on shares of Corcept Therapeutics in a research note on Friday, September 18th. Finally, Weiss Ratings raised Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $138.17.

Read Our Latest Report on CORT

Institutional Trading of Corcept Therapeutics

A number of large investors have recently made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corcept Therapeutics during the second quarter worth $27,000. State of Wyoming increased its holdings in shares of Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares during the period. IFP Advisors Inc raised its position in shares of Corcept Therapeutics by 568.4% in the 2nd quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 773 shares in the last quarter. Freestone Grove Partners LP bought a new position in shares of Corcept Therapeutics in the 2nd quarter worth $87,000. Finally, Gould Capital LLC raised its position in shares of Corcept Therapeutics by 66.7% in the 1st quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 400 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing medicines that modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol activity in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s principal commercial product is Korlym (mifepristone), a glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery.